App-Quantinova.ai

Preferential Use of Coagulation Pathways Differs between Classical Myeloproliferative Neoplasms: Results of Global Coagulation Assays with Respect to Clinical and Genetic Features

Alessandro Lucchesi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Albyl-E

Gaps in the Assessment and Monitoring of Cardiovascular Risk and Psychological Burden in Polycythemia Vera: Landmark 2.0, a Worldwide Health Survey

Jean-Jacques Kiladjian - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Polycythemia vera

N/A

In Search of Drivers of CD34+/CD38-/CD26+ Leukemia Stem Cells Persistence in CML Patients

Paola Pacelli - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

L-Tyrosine

Expression Profiles of Human Endogenous Retrovirus in Chronic Myeloid Leukemia at Diagnosis and after TKI Therapy

Maria Monne - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

L-Tyrosine

Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases

Alessandro Andriani - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Treatment- Free Remission in Chronic Myeloid Leukemia -Experience of a Single Brazilian Private Institution Using Imatinib Copies

Renato Torrescasana Centrone - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

Imatinib

Coexisting Myeloproliferative and Lymphoproliferative Neoplasms: A European Multicenter Retrospective Study

Dolly Viviana Viviana Fiallo Suarez - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Chronic Lymphocytic Leukemia

Ruxolitinib phosphate

Thrombosis in Tregs-Induced Thrombocithopenia in Patients with Myelofibrosis

Rossella Rosari Cacciola - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Deep vein thrombosis

Epinephrine

Molecular and Clinical Spectra of Protein Phosphatase, Mg2+/Mn2+-Dependent 1D (PPM1D)-Mutant Myeloid Neoplasms

Mai M M Aly - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hematological malignancies

TP53

Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine

Valeria Santini - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelodysplastic Syndrome

Azacitidine

Luspatercept in Combination with Recombinant-Erythropoietin in MDS RS Patients: Stimulating Early and Late Erythropoiesis

Francesco Versino - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Anemia

Recombinant human erythropoietin

Immune Response to Covid-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia (CLL): An Experience from Two Italian Centres

Idanna Innocenti - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic Lymphocytic Leukemia

N/A

Bone Marrow-Free Sequencing of M Protein Genes in Monoclonal Gammopathies

Alice Nevone - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

AL Amyloidosis

N/A

Real-World Treatment Patterns of Patients Initiating Third-Line Therapy in Relapsed or Refractory Multiple Myeloma in Europe

Moritz Lehne - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

VEGF and IL-6 As Markers of Severity and Response to Treatment in Waldenstrom Macroglobulinemia and IgM-Monoclonal Gammopathy of Undetermined Significance: A Monocentric Experience

Annamaria Tomasso - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Waldenstrom’s macroglobulinemia

Interleukin

Clinical Features and Treatment Response in Patients with Multiple Myeloma and CD20 Expression: Real-Life Experience of the Centro-Italy Multiple Myeloma Macroregional District

Alessia Fiorini - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Real-Life Outcome of Patients with Newly Diagnosed Symptomatic Multiple Myeloma Treated with VTD Induction Followed By Single or Double ASCT: A Retrospective Analysis from a Single Institution

Fabio Serpenti - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dental and Oral Health

Oral cancer

Cyclophosphamide

Combination of DLI to Blinatumomab in Post- Transplant Molecular Relapse of Pediatric High- Risk ALL

Fabiana Cacace - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

B-cell acute lymphoblastic leukemia

Blinatumomab

Early Collected Leukapheresis Material Improves Tisagenlecleucel Manufacturing Success and Time from Order to Pickup of the Leukapheresis Product: A Real-World Experience

Tina Smrekar - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Diffuse large B-cell lymphoma

tisagenlecleucel-t

Treosulfan Therapeutic Drug Monitoring: Optimizing Conditioning Therapy in Pediatric Hematopoietic Stem Cell Transplantation

Francesco Delle Cave - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

treosulfan

Filters

30348 Abstracts